Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo

Journal of the Medical Association of Thailand

Volumn 93, Issue 10, 2010, Pages 1188-1195

  Kosuwon, Weerachai ^a   Sirichatiwapee, Winai ^a   Wisanuyotin, Tweechok ^a   Jeeravipoolvarn, Polsak ^a   Laupattarakasem, Wiroon ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

0.0125 capsaicin gel; OA knee

Indexed keywords

CAPSAICIN; CAPSIKA GEL; PLACEBO; UNCLASSIFIED DRUG; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS;

ADULT; AGED; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; JOINT STIFFNESS; KNEE FUNCTION; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; CAPSAICIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; SENSORY SYSTEM AGENTS; TREATMENT OUTCOME;

EID: 77958085940     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Murray C, Lopez A. The global burden of disease. Geneva: World Health Organisation; 1997.
2. Copper C. Epidemiology of osteoarthritis. In: Klipple J, Dieppe P, editors. Rheumatology. 2nd ed. London: Mosby; 1998: 1-20.
3. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-55.
4. Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 1995; 7: 317-28.
5. Niethard FU, Gold MS, Solomon GS, Liu JM, Unkauf M, Albrecht HH, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005; 32: 2384-92.
6. Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991; 13: 383-95.
7. Zhang WY, Li Wan PA. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994; 46: 517-22.
8. McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 1992; 19: 604-7.
9. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16: 494-502.
10. Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss views. J Rheumatol 1999; 26: 2664-74.
11. Machin D, Campbell MJ. Design of studies for medical research. Chichester, West Sussex: Wiley; 2005.
12. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795-808.
13. Maggi CA. Tachykinins and calcitonin generelated peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol 1995; 45: 1-98.
14. Szolcsanyi J. Capsaicin-sensitive sensory nerve terminals with local and systemic efferent functions: facts and scopes of an unorthodox neuroregulatory mechanism. Prog Brain Res 1996; 113: 343-59.
15. Lam FY, Ferrell WR. Neurogenic component of different models of acute inflammation in the rat knee joint. Ann Rheum Dis 1991; 50: 747-51.
16. Marabini S, Matucci-Cerinic M, Geppetti P, Del Bianco E, Marchesoni A, Tosi S, et al. Substance P and somatostatin levels in rheumatoid arthritis, osteoarthritis, and psoriatic arthritis synovial fluid. Ann N Y Acad Sci 1991; 632: 435-6.
17. Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E. Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol 1991; 20: 326-35.
18. Nagy I, Santha P, Jancso G, Urban L. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 2004; 500: 351-69.
19. Carpenter SE, Lynn B. Vascular and sensory responses of human skin to mild injury after topical treatment with capsaicin. Br J Pharmacol 1981; 73: 755-8.
20. McMahon SB, Lewin G, Bloom SR. The consequences of long-term topical capsaicin application in the rat. Pain 1991; 44: 301-10.
21. Westerman RA, Roberts RG, Kotzmann RR, Westerman DA, Delaney C, Widdop RE, et al. Effects of topical capsaicin on normal skin and affected dermatomes in herpes zoster. Clin Exp Neurol 1988; 25: 71-84.
22. Pacifici M, Nelson FRT, Hansma PK. On the horizon from the ORS. J Am Acad Orthop Surg 2008; 16: 616-8.